Mangwana Sadhana
Department of Blood Transfusion Services, Sri Balaji Action Medical Institute, Paschim Vihar, New Delhi, India.
Asian J Transfus Sci. 2015 Jul-Dec;9(2):177-80. doi: 10.4103/0973-6247.154253.
Emerging infectious diseases pose threats to the general human population; including recipients of blood transfusions. Dengue is spreading rapidly to new areas and with increasing frequency of major outbreaks. Screening blood for dengue antigens in dengue-endemic countries would be costly and should, therefore, be recommended only after careful assessment of risk for infection and cost.
A prospective study was conducted to establish the magnitude of the threat that dengue poses to blood safety where it is sporadic with seasonal variations, to quantify risk and to assess that whether screening is feasible and cost-effective.
Nonstructural protein 1 (NS1) antigen test was done on 1709 donations during dengue outbreak in the months August to November 2013 as an additional test using Bio-Rad Platelia Dengue NS1AG test kit which is one step sandwich format microplate enzyme immunoassay using murine monoclonal antibodies for capture and revelation. Chi-square test was used to find statistical significance.
Majority cases were whole blood, replacement, male donors with 76.10% donors in <35 years age group. About 17.85% were single donor platelet donations. NS1 antigen in all donors was negative. In the past, dengue affected mainly children who do not donate blood. With the changing trend, mean age of infection increased affecting the population that does donate blood, further reducing blood donation pool. Further studies need to be done in different geographic regions of the country during dengue transmission season to establish maximum incidence of viremic donations, rates of transfusion transmission and clinical consequences in recipients. If risk is found to be substantial, decision will be taken by the policymakers at what threshold screening should be instituted to ensure safe blood transfusion.
新发传染病对普通人群构成威胁,包括输血接受者。登革热正在迅速传播到新的地区,且重大疫情爆发的频率不断增加。在登革热流行国家对血液进行登革热抗原筛查成本高昂,因此,只有在仔细评估感染风险和成本后才应予以推荐。
开展一项前瞻性研究,以确定在登革热呈散发性且有季节性变化的地区,登革热对血液安全构成的威胁程度,量化风险,并评估筛查是否可行及具有成本效益。
在2013年8月至11月登革热疫情期间,使用Bio-Rad Platelia Dengue NS1AG检测试剂盒对1709份献血进行非结构蛋白1(NS1)抗原检测,该试剂盒采用一步夹心式微孔板酶免疫测定法,使用鼠单克隆抗体进行捕获和显色。采用卡方检验来确定统计学意义。
多数献血为全血、替代献血,男性献血者居多,76.10%的献血者年龄在35岁以下。约17.85%为单采血小板献血。所有献血者的NS1抗原均为阴性。过去,登革热主要影响不献血的儿童。随着趋势的变化,感染的平均年龄增加,影响到献血人群,进一步减少了献血储备。在该国不同地理区域的登革热传播季节还需要进一步开展研究,以确定病毒血症献血的最高发生率、输血传播率以及受血者的临床后果。如果发现风险很大,政策制定者将决定应在何种阈值下进行筛查以确保安全输血。